DUBLIN, May 4, 2022 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2022, raised 2022 financial guidance and provided business updates. We’re pleased to...
Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results Closed GW Pharmaceuticals plc Acquisition, Creating an Innovative, High-Growth, Global Biopharma Leader 41% of Net Product Sales from Recently Launched or...
GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones Total preliminary net product sales of approximately $148 million for the fourth...
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress Total revenue increased 51 percent to $137.1 million Epidiolex for seizures associated with TSC launched in the...
FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex – Age-range for all EPIDIOLEX indications expanded to include patients one year of age and...
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress – Total revenue of $120.6 million – – Total Epidiolex® net product sales of $116.1 million –...
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019 Epidiolex U.S. year to date net sales of $188.0 million, including Q3...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019 Epidiolex U.S. Q1 net sales of $33.5m Positive Phase 3 pivotal results...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018 Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine, launched in the...
A post on Twitter today has pressured GW Pharma (NASDAQ: GWPH), which dipped more than 3% to $145.21. The post, by Ryan Flinn, a Bay Area journalist in healthcare...
Do U.S. Cannabis Industry Investments Face Risk Of Federal Enforcement Action? Theoretically Yes, Practically No Guest post by David Wenger The US cannabis industry is intriguing to investors. But...
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared...
The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V...
GW Pharmaceuticals (NASDAQ: GWPH) released financials for its fiscal 2018 Q3 after the close today and hosted a conference call for investors and analysts. Readers can access a full...
FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy June 25, 2018 The U.S. Food and Drug Administration today...
Last week, GW Pharma (NASDAQ: GWPH) scored a milestone victory, as the thirteen-member panel at the Peripheral and Central Nervous System Drugs Advisory Committee, which met on April 19th to consider...
The potentially first botanically-derived FDA-approved cannabis-based product moved closer to approval today, as an Advisory Committee discussed the safety and efficacy of Epidolex, intended to treat seizures in children...
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex(R) (cannabidiol) Study in The Lancet First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare,...
GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) —...
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress Epidiolex® (cannabidiol) NDA Submitted to FDA Conference call today at 7:30 a.m. EST LONDON...
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome...
GW Pharma (NASDAQ: GWPH) issued a press release after the close of trading on Monday to report its FY17-Q3 financials and provide an operational update. The most significant news...
Earlier this week, we highlighted a story published on Leafly regarding lobbying efforts by GW Pharma (NASDAQ: GWPH). Leafly’s Bruce Barcott discovered that GW Pharma and its U.S. subsidiary,...
Note: We published a follow up to this article Leafly’s Bruce Barcott has uncovered some actions taken by GW Pharma (NASDAQ: GWPH) that appear to be part of an...
